Meglitinides are oral agents that can be used by patients with noninsulin dependent diabetes mellitus. It should be used appropriately if an optimum benefit is to be achieved.
Mechanism of action: stimulation of insulin secretion from a functioning pancreas
(1) hypersensitivity to a meglitinide
(2) diabetic ketoacidosis
(3) no cellular sources of insulin:
(3a) Type 1 diabetes mellitus
(3b) absence of a functioning pancreas
(1) pregnancy (safety not established)
(2) breastfeeding (safety not established)
(3) failure to respond to sulfonylureas
(1) The dose must be taken immediately before the meal. If the patient does not eat then the dose should not be taken. A dose should not be taken after a meal if not taken before.
(2) A meglitinide should not be used in combination with a sulfonylurea.
To read more or access our algorithms and calculators, please log in or register.
Purpose: To identify contraindications and the need to take precautions when using a meglitinide in a patient with diabetes mellitus? (Y or N)
Specialty: Endocrinology, Clinical Laboratory
Objective: risk factors, prevention
ICD-10: E10-E14, T38.3,